Rajpal, Arvind,Cho, Helen Kim,Jooss, Karin Ute,Abdiche, Yasmina Noubia,Youssef, Sawsan,Ho, Weihsien
申请号：
NZ73173515
公开号：
NZ731735A
申请日:
2015.12.02
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
The present invention provides structurally defined antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases. The structurally defined anti-PD-1 antibody comprises HCDR1 of GYTFTSYWIN； HCDR2 of NIX1PGSSX2TNYNEKFKN, wherein X1 is Y or W, and X2 is L, I, or S； HCDR3 of LX1TGTFAY, wherein X1 is L or S； LCDR1 of KSSQSLX1DSX2NOKNFLT, wherein X1 is W or L, and X2 is G or T； LCDR2 of WTSX1RES, wherein X1 is T or Y； and LCDR3 of QNDYX1YPX2T, wherein X1 is F or S, and X2 is L or H.
